Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?

Over the last decade, the therapeutic scenario for advanced non-small-cell lung cancer (NSCLC) has undergone a major paradigm shift. Immune checkpoint inhibitors (ICIs) have shown a meaningful clinical and survival improvement in different settings of the disease. However, the real benefit of this t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronte, Giuseppe, Cosi, Donato Michele, Magri, Chiara, Frassoldati, Antonio, Crinò, Lucio, Calabrò, Luana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454231/
https://www.ncbi.nlm.nih.gov/pubmed/37628803
http://dx.doi.org/10.3390/ijms241612622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454231/
https://www.ncbi.nlm.nih.gov/pubmed/37628803
http://dx.doi.org/10.3390/ijms241612622

Ejemplares similares